Annovis Bio (NYSE: ANVS) will deliver three presentations at the 19th Clinical Trials on Alzheimer's Disease (CTAD) conference, scheduled for Nov. 16-19, 2026, in Boston, focusing on its investigational oral therapy buntanetap. The presentations will cover the drug's mechanism of action targeting neurotoxic proteins, the design and baseline characteristics of its pivotal Phase 3 study in early Alzheimer's disease, and the use of artificial intelligence to predict blood-brain barrier permeability of late-stage Alzheimer's drug candidates.
The conference program includes an oral presentation on Nov. 19 by Alexander Morin, director of strategic communications, and two poster presentations on Nov. 16-17, one of which will be delivered by Chief Scientific Officer Cheng Fang. These presentations come as Annovis approaches a pivotal clinical data readout in early 2027 and prepares for a New Drug Application.
The significance of these presentations lies in their potential to validate buntanetap's differentiated approach. Unlike therapies that target a single protein, buntanetap is designed to inhibit the translation of multiple neurotoxic proteins—including APP and amyloid beta, tau, alpha-synuclein, and TDP-43—through a specific RNA-targeting mechanism. By addressing underlying causes of neurodegeneration, the company aims to halt disease progression and improve cognitive and motor functions in patients with Alzheimer's and Parkinson's disease.
The AI-driven blood-brain barrier permeability prediction presentation is particularly noteworthy because it could streamline the development of other Alzheimer's drug candidates. If the AI model proves predictive, it may reduce reliance on costly and time-consuming animal studies, accelerating the pace of drug discovery in a field where effective treatments remain scarce.
For investors, the CTAD presentations could serve as a catalyst ahead of the 2027 data readout. The Phase 3 trial design and baseline characteristics will provide insight into the study's statistical power and patient population, which are critical factors for regulatory success. The company's progress is detailed in its newsroom, and additional information about Annovis Bio (NYSE: ANVS) is available through NetworkNewsWire. The full press release can be viewed at https://nnw.fm/2k4SQ, and the company's website is www.annovisbio.com.
NetworkNewsWire, a specialized communications platform, is part of the Dynamic Brand Portfolio at IBN, which provides InvestorWire and editorial syndication to 5,000+ outlets, among other services. The platform's corporate communications solutions help companies like Annovis reach a broad investor audience. Full terms of use and disclaimers are available on the NetworkNewsWire website.
